» Articles » PMID: 33396321

Extracellular MiRNAs for the Management of Barrett's Esophagus and Esophageal Adenocarcinoma: A Systematic Review

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Jan 5
PMID 33396321
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Esophageal adenocarcinoma (EAC), the major histologic type of esophageal cancer (EC) in Western countries, is a disease with a poor prognosis, primarily due to usual diagnosis at an advanced stage. The prevalence of EAC has increased in recent years, both in Western countries and in Asia. Barrett's esophagus (BE) is a precursor lesion of EAC. Therefore, early detection and proper management of BE and EAC is important to improve prognosis. Here, we systematically summarize current knowledge about the potential utility of extracellular microRNAs (miRNAs), which are thought to be non-invasive biomarkers for many diseases, for these purposes. A search of the PubMed and Embase databases identified 22 papers about extracellular miRNAs that have potential utility for management of EAC. Among them, 19 were EAC-related and ten were BE-related; some of these dealt with both conditions. The articles included studies reporting diagnosis, prognosis, and treatment responses. Multiple papers report dysregulation of miR-194-5p in BE and miR-21-5p, -25-3p, and -93-5p in EAC. Although it will take time to utilize these miRNAs in clinical practice, they are likely to be useful non-invasive markers in the future.

Citing Articles

Epigenetic Alterations from Barrett's Esophagus to Esophageal Adenocarcinoma.

Ergun P, Kipcak S, Bor S Int J Mol Sci. 2023; 24(9).

PMID: 37175524 PMC: 10178512. DOI: 10.3390/ijms24097817.


Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples.

Masque-Soler N, Gehrung M, Kosmidou C, Li X, Diwan I, Rafferty C EBioMedicine. 2022; 76:103814.

PMID: 35051729 PMC: 8883000. DOI: 10.1016/j.ebiom.2022.103814.


Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.

Maslyonkina K, Konyukova A, Alexeeva D, Sinelnikov M, Mikhaleva L Cancer Med. 2021; 11(2):447-478.

PMID: 34870375 PMC: 8729054. DOI: 10.1002/cam4.4447.

References
1.
Wei H, Cui R, Bahr J, Zanesi N, Luo Z, Meng W . miR-130a Deregulates PTEN and Stimulates Tumor Growth. Cancer Res. 2017; 77(22):6168-6178. PMC: 7081380. DOI: 10.1158/0008-5472.CAN-17-0530. View

2.
Chen P, Zhao L, Pan X, Jin L, Lin C, Xu W . Tumor suppressor microRNA-136-5p regulates the cellular function of renal cell carcinoma. Oncol Lett. 2018; 15(4):5995-6002. PMC: 5844007. DOI: 10.3892/ol.2018.8081. View

3.
Shi H, Shen H, Xu J, Zhao S, Yao S, Jiang N . MiR-143-3p suppresses the progression of ovarian cancer. Am J Transl Res. 2018; 10(3):866-874. PMC: 5883127. View

4.
Souza R, Krishnan K, Spechler S . Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol. 2008; 295(2):G211-8. DOI: 10.1152/ajpgi.90250.2008. View

5.
Chen X, Luo H, Li X, Tian X, Peng B, Liu S . miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer. Carcinogenesis. 2018; 39(8):1006-1015. DOI: 10.1093/carcin/bgy074. View